ICCBH2017 Poster Presentations (1) (209 abstracts)
1Institute of Orthopedics and Traumatology, Kiev, Ukraine; 2Institute of Gerontology, Kiev, Ukraine.
Purpose: To explore the features of bone metabolism and create a system of medical correction of violations in patients with Ehlers-Danlos syndrome.
Materials and methods: Based on the analysis of the survey results of 12 patients with different types of EDS aged 3 to 10 years (males - 8 patients, female - 4 patients) who were treated in Institute of Orthopedics and Traumatology,National Academy of Medical Sciences, Kiev, Ukraine from 2005 to 2015 years. Bone metabolism was studied by examining markers of bone turnover as recommended by the International Organization of osteoporosis (International Osteoporosis Fundation) by ELISA on the analyzer ELECSYS firm ROCHE (Roche Diagnostics, Germany) using test systems Cobas in terms of biochemical laboratory control ITO NAMS. Among the markers of bone formation were: propeptydy procollagen of type I (P1NP), state osteo resorption reflect the level of β-CTx in blood serum. The level of osteocalcin (OC) - the rate of bone remodeling.
Results and discussion: Changes in bone markers and vitamin 25 (OH) D in most patients show the violation in bone metabolism in patients with EDS, including the synthesis and degradation of type I of collagen, imbalance between the processes of bone formation and osteo resorption; differing vectors changes in bone formation, increased bone resorption in most patients, acceleration remodeling at both types of EDS; reducing the concentration of vitamin 25 (OH) D, which negatively affects the formation and mineralization of bone. So, all of the above written points to the need and feasibility of developing a system of drug correction of change of bone metabolism.
Conclusion: Indicators of bone markers and vitamin 25 (OH) show the violation in bone metabolism in patients with EDS, synthesis and degradation of collagen type I, imbalance between the processes of bone formation and bone resorption.
Disclosure: The authors declared no competing interests.